The small molecule CB-103, combined with the non-steroidal AIs anastrozole or letrozole (Figure 10C), is being investigated for treating HR+/HER2-advanced breast cancer patients who have previously benefited from AI therapy (NCT04714619, Table 3). This evidence concerns the gene ERBB2 and breast carcinoma.